Evaluation of the Venous Thrombotic Biological Profile of Different PCOS Phenotypes: French Cross-sectional Study
The study, sponsored by Fondation Hôpital Saint-Joseph, aims to evaluate the venous thrombotic biological profile across various PCOS phenotypes, addressing a significant gap in understanding the cardiovascular risks associated with PCOS. With PCOS being the most prevalent endocrine disorder among women of childbearing age, the findings could lead to improved clinical management and personalized treatment strategies, potentially enhancing the market for diagnostic tests and therapeutic interventions targeting PCOS. The competitive landscape may include other diagnostic and therapeutic entities focused on PCOS and related cardiovascular risks, necessitating thorough diligence to identify potential partnerships or acquisition targets.
Indication: Polycystic Ovary Syndrome
Modality: protein therapy
Target: Thrombotic biological markers related to venous thromboembolism (VTE) risk in women with different phenotypes of Polycystic Ovary Syndrome (PCOS).
Sponsor: Fondation Hôpital Saint-Joseph
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 11, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Thrombotic biological markers related to venous thromboembolism (VTE) risk in women with different phenotypes of Polycystic Ovary Syndrome (PCOS).
View original source fields
Condition raw: Polycystic Ovary Syndrome
Condition normalized: Polycystic Ovary Syndrome
Modality raw: protein therapy
Modality normalized: protein therapy
Target raw: Thrombotic biological markers related to venous thromboembolism (VTE) risk in women with different phenotypes of Polycystic Ovary Syndrome (PCOS).
Target normalized: Thrombotic biological markers related to venous thromboembolism (VTE) risk in women with different phenotypes of Polycystic Ovary Syndrome (PCOS).